<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>29(3)</volume><submitter>Dillard P</submitter><funding>Norges Forskningsråd</funding><funding>Helse Sør-Øst RHF</funding><pubmed_abstract>T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for adoptive cell therapy. We isolated a novel hTERT-specific TCR sequence, named Radium-4, from a clinically responding pancreatic cancer patient vaccinated with a long hTERT peptide. Radium-4 TCR-redirected primary CD4&lt;sup>+&lt;/sup> and CD8&lt;sup>+&lt;/sup> T cells demonstrated in vitro efficacy, producing inflammatory cytokines and killing hTERT&lt;sup>+&lt;/sup> melanoma cells in both 2D and 3D settings, as well as malignant, patient-derived ascites cells. Importantly, T cells expressing Radium-4 TCR displayed no toxicity against bone marrow stem cells or mature hematopoietic cells. Notably, Radium-</pubmed_abstract><journal>Molecular therapy : the journal of the American Society of Gene Therapy</journal><pagination>1199-1213</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7934585</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.</pubmed_title><pmcid>PMC7934585</pmcid><pubmed_authors>Mælandsmo GM</pubmed_authors><pubmed_authors>Kvalheim G</pubmed_authors><pubmed_authors>Walchli S</pubmed_authors><pubmed_authors>Gaudernack G</pubmed_authors><pubmed_authors>Pollmann S</pubmed_authors><pubmed_authors>Winge-Main A</pubmed_authors><pubmed_authors>Florenes VA</pubmed_authors><pubmed_authors>Myhre MR</pubmed_authors><pubmed_authors>Inderberg EM</pubmed_authors><pubmed_authors>Maggadottir SM</pubmed_authors><pubmed_authors>Koksal H</pubmed_authors><pubmed_authors>Menard M</pubmed_authors><pubmed_authors>Dillard P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.</name><description>T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for adoptive cell therapy. We isolated a novel hTERT-specific TCR sequence, named Radium-4, from a clinically responding pancreatic cancer patient vaccinated with a long hTERT peptide. Radium-4 TCR-redirected primary CD4&lt;sup>+&lt;/sup> and CD8&lt;sup>+&lt;/sup> T cells demonstrated in vitro efficacy, producing inflammatory cytokines and killing hTERT&lt;sup>+&lt;/sup> melanoma cells in both 2D and 3D settings, as well as malignant, patient-derived ascites cells. Importantly, T cells expressing Radium-4 TCR displayed no toxicity against bone marrow stem cells or mature hematopoietic cells. Notably, Radium-</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2026-04-08T14:45:31.653Z</modification><creation>2025-02-19T03:26:54.809Z</creation></dates><accession>S-EPMC7934585</accession><cross_references><pubmed>33212301</pubmed><doi>10.1016/j.ymthe.2020.11.019</doi></cross_references></HashMap>